Details for Patent: 11,065,250

« Back to Dashboard

Which drugs does patent 11,065,250 protect, and when does it expire?

Patent 11,065,250 protects IBRANCE and is included in one NDA.

Protection for IBRANCE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-eight patent family members in thirty-three countries.

Summary for Patent: 11,065,250

Title:	Solid dosage forms of palbociclib
Abstract:	The present invention relates to solid dosage forms of palbociclib comprising a water-soluble acid. The dosage forms described herein have desirable pharmacokinetic characteristics.
Inventor(s):	Fady Makram Louiz Ibrahim, Matthew Patrick Mullarney, Ravi M. Shanker, Barbara Rodriguez Spong, Jian Wang
Assignee:	Pfizer Corp SRL
Application Number:	US15/578,410
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,065,250
Patent Claim Types: see list of patent claims	Compound; Dosage form;

Drugs Protected by US Patent 11,065,250

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-001	Nov 1, 2019		RX	Yes	No	11,065,250*PED				Y
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-002	Nov 1, 2019		RX	Yes	No	11,065,250*PED				Y
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-003	Nov 1, 2019		RX	Yes	Yes	11,065,250*PED				Y

Foreign Priority and PCT Information for Patent: 11,065,250

PCT Information
PCT Filed	May 24, 2016	PCT Application Number:	PCT/IB2016/053040
PCT Publication Date:	December 08, 2016	PCT Publication Number:	WO2016/193860

International Family Members for US Patent 11,065,250

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	104909
Australia	2016272881
Australia	2019204689